With both S-pindolol and S-oxprenolol, Actimed has the opportunity to develop effective treatments for cancer cachexia and other muscle-wasting conditions, which have the potential to bring ...

Halting the advance of a muscle wasting condition called cachexia, could improve quality of life for cancer sufferers. For many years, oncologists and researchers thought the dramatic weight-loss ...

Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Historically, cachexia has not been fully understood. Also known as wasting syndrome, cachexia is often incorrectly viewed as simply an inevitable side effect to cancer and other chronic conditions.

Cachexia is a wasting syndrome prevalent in cancer patients (as well as patients with other conditions) that is marked by ...

Measures of appetite and cachexia were improved, along with physical activity, in the 400 mg ponsegromab group relative to ...

Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with advanced cancer. A new study from Japan has revealed that lower cachexia rates, particularly with ...